class switching in the heavy-chain constant region, and increased affinity for antigen in the variable region. In 1991, I was invited to work at the National Institutes of Health as a Fogarty Scholar.

Bio, Inc. has announced a licensing agreement with AstralBio Inc. for a first-in-class antibody designed to target Activin E, a key factor in regulating energy balance and fat distribution.